Our New Study Shows That The Science Of Cannabis And Sleep Extends Beyond THC (Op-Ed)
“We found that the strongest evidence for improving sleep was associated with cannabidiol (CBD), cannabinol (CBN) and combinations of the two—but not primarily THC.” By Andrea Efre, University of South Florida College of Nursing The cannabis sleep market represents a shift away from traditional pharmaceuticals toward a natural alternative. Historically, cannabis products marketed for sleep […]
VA Documents Reveal Rules For Medical Cannabis Conversations Between Veterans And Government Doctors (Op-Ed)
“They cannot currently help a veteran access cannabis through official channels. This is not a gray area. It is a bright line that shapes every clinical interaction.” By Mike Davis, Veterans Action Council What happens when a veteran sits down with a clinician in a U.S. Department of Veterans Affairs (VA) medical center and mentions […]
Tariffs’ Impact On Some Cannabis Businesses May Erase Any Benefits They See From 280E Tax Relief Under Rescheduling (Op-Ed)
“Rescheduling removes a major structural penalty, but tariffs will reshape who captures the gains. All else equal, dispensary-heavy companies may emerge as the primary beneficiaries.” By Justin Leiby, Cannabis Research Institute With federal cannabis rescheduling partially underway and the potential end of the 280E tax penalty approaching, how much relief the cannabis industry will experience […]
The 2026 Elections Matter More For Cannabis Than The Next Bill Filed In Congress (Op-Ed)
“The next phase of cannabis policy will not be decided by a single bill. It will be shaped by the political environment that determines whether any bill has a path.” By Jordan Isenstadt, National Cannabis Industry Association The cannabis industry loves a headline bill. The Secure and Fair Enforcement (SAFE) Banking Act. Rescheduling. Federal reform. […]
Trump’s Medical Marijuana Move Focused On Helping Ailing Seniors, But Lack Of Coordination Could Cause Backlash (Op-Ed)
“The rush to provide senior citizens with medical marijuana will require considerable legal, scientific and commercial infrastructures, which, in an ideal world, would avoid repeating historical mistakes by forming with clarity and coordination.” By Emily Dufton Everyone knows that last month was historic for cannabis. Big changes are afoot with medical marijuana’s rescheduling and federal […]
Trump’s Marijuana Rescheduling Move Is A ‘Step Forward,’ But Still ‘Falls Well Short’ Of Needed Changes (Op-Ed)
“To rectify this state/federal conflict…cannabis must be removed from the Controlled Substances Act altogether.” By Paul Armentano, NORML The Trump administration’s decision to reclassify state-authorized medical cannabis products and recognize state-licensed medical cannabis providers is a historic first step toward bringing federal drug policy into the 21st century. For over 50 years, the federal government […]
The Cannabis Beverage Industry Has An Evidence Problem, With Too Few Companies Submitting Products For Independent Scrutiny (Op-Ed)
“The industry cannot ask for nuanced, evidence-informed regulation while simultaneously declining to produce the evidence that would make that possible.” By Leah Kollross, 23rd State Cannabis beverages are one of the fastest-growing segments in the hemp and cannabis marketplace, and one of the most structurally vulnerable to regulatory backlash. The reason has less to do […]
Federal Marijuana Rescheduling Will End Discrimination In Housing, Healthcare And Employment For Medical Cannabis Patients (Op-Ed)
“These products are now federally recognized as legitimate medicine… Patients and their caregivers are no longer considered criminals under federal law. They have federal rights.” By Steph Sherer, Americans for Safe Access The Department of Justice and Drug Enforcement Administration’s rescheduling of cannabis is more than just validation for the millions of Americans who rely […]